FDA Panel Supports Roche HPV Assay To Replace Pap As Primary Cervical Cancer Screen
This article was originally published in The Gray Sheet
Executive Summary
The Microbiology Devices Panel provided unanimous support Roche’s submission to upgrade labeling for it cobas HPV test as a first-line, primary screen for cervical cancer.